Results 41 to 50 of about 14,657 (135)

Preoperative zoledronic acid therapy prevent hungry bone syndrome in patients with primary hyperparathyroidism

Indian Journal of Endocrinology and Metabolism, 2017
Background: Hungry bone syndrome is a common complication of surgery for primary hyperparathyroidism in India which often leads to prolonged hospitalization. There are varying reports on the use and efficacy of bisphosphonates in the prevention of hungry
Sabaretnam Mayilvaganan, H A Vijaya Sarathi, C Shivaprasad   +2 more
doaj   +1 more source

Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid

Haematologica, 2006
Osteonecrosis of the jaw (ONJ) has been associated with the use of pamidronate and zoledronic acid. ONJ was assessed prospectively since July 2003 in 202 patients with multiple myeloma (MM) who received bisphosphonates since April 1995. Fifteen patients (
MA Dimopoulos, E Kastritis, A Anagnostopoulos, I Melakopoulos, D Gika, LA Moulopoulos, C Bamia, E Terpos, K Tsionos, A Bamias   +9 more
doaj  

Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture

Therapeutics and Clinical Risk Management, 2009
Roland D ChapurlatINSERM U831, Université de Lyon, Division of Rheumatology, Hôpital E Herriot, Hospices Civils de Lyon, Lyon, FranceBackground: Several treatments for postmenopausal osteoporosis have been available in the past ...
Rol, D Chapurlat
doaj  

Remarkable Regression of an Osteolytic Lesion of Large Cell Lung Cancer Treated with Zoledronic Acid: A Case Report

Case Reports in Oncology, 2012
Zoledronic acid suppresses osteoclastic changes and reduces the risk of cancer-induced skeletal-related events. Moreover, it has been reported to have antitumor effects.
Sadayuki Kawai, Gengo Yamaura, Katsuhiro Yasuda, Takao Suzuki   +3 more
doaj   +1 more source

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

Health Technology Assessment, 2013
Background: Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.
J Ford, E Cummins, P Sharma, A Elders, F Stewart, R Johnston, P Royle, R Jones, C Mulatero, R Todd, G Mowatt   +10 more
doaj   +1 more source

Zoledrinic Acid Induces Steoblastic Differentiation of Mesenchymal Stem Cells without Change in Hypomethylation Status of OSTERIX Promoter [PDF]

Cell Journal, 2012
Objective: Mechanism of zoledronic acid on osteoblastic differentiation of mesenchymal stem cells (MSCs) has not fully understood. With the knowledge of some drugs mechanism that alter methylation pattern of some genes, the present research sets out to ...
Maryam Mahmodinia Maymand, Saeid Kaviani, Masoud Soleimani, Yousef Mortazavi, Mehrdad Noruzinia, Majid Farshdousti Hagh   +5 more
doaj  

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Clinical Interventions in Aging, 2008
Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, GreeceAbstract: Zoledronic acid is a nitrogen-containing, third-generation ...
Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias   +4 more
doaj  

Zoledronic acid in the management of metastatic bone disease

Therapeutics and Clinical Risk Management, 2008
Thomas J Polascik, Vladimir MouravievDuke Prostate Center and Division of Urologic Surgery, Duke University Medical Center, Durham, NC, USAAbstract: Many patients with advanced cancer experience decreased bone strength due to metastatic foci, underlying ...
Thomas J Polascik, Vladimir Mouraviev
doaj  

Zoledronic acid for chronic kidney disease-associated osteoporosis. [PDF]

Arch Osteoporos
Sakthivel S, Kjærgaard KD, Ivarsen P, Langdahl B, Jørgensen HS.   +4 more
europepmc   +1 more source

Myeloid cell reprogramming combined with zoledronic acid effectively suppresses bone metastasis. [PDF]

Cancer Biol Med
Luo Y, Cai Y, Jiang Z, Zheng K, Ren S, Yu L, Liu B, Shi T, Wei J.   +8 more
europepmc   +1 more source